These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 38275509)
21. Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy. Nakahara J; Maeda M; Aiso S; Suzuki N Clin Rev Allergy Immunol; 2012 Feb; 42(1):26-34. PubMed ID: 22189514 [TBL] [Abstract][Full Text] [Related]
22. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis. Neuberger EE; Abbass IM; Jones E; Engmann NJ Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713 [TBL] [Abstract][Full Text] [Related]
23. The Efficacy of Psychological Interventions for Managing Fatigue in People With Multiple Sclerosis: A Systematic Review and Meta-Analysis. Phyo AZZ; Demaneuf T; De Livera AM; Jelinek GA; Brown CR; Marck CH; Neate SL; Taylor KL; Mills T; O'Kearney E; Karahalios A; Weiland TJ Front Neurol; 2018; 9():149. PubMed ID: 29670565 [TBL] [Abstract][Full Text] [Related]
24. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Brañas P; Jordan R; Fry-Smith A; Burls A; Hyde C Health Technol Assess; 2000; 4(27):1-61. PubMed ID: 11074395 [TBL] [Abstract][Full Text] [Related]
25. Disease-modifying therapy for multiple sclerosis: Implications for gut microbiota. Pilotto S; Zoledziewska M; Fenu G; Cocco E; Lorefice L Mult Scler Relat Disord; 2023 May; 73():104671. PubMed ID: 37001407 [TBL] [Abstract][Full Text] [Related]
26. Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool. Col NF; Solomon AJ; Alvarez E; Pbert L; Ionete C; BerriosMorales I; Chester J; Kutz C; Iwuchukwu C; Livingston T; Springmann V; Col HV; Ngo LH Mult Scler Relat Disord; 2023 Dec; 80():105092. PubMed ID: 37931489 [TBL] [Abstract][Full Text] [Related]
27. Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis. Bross M; Hackett M; Bernitsas E Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560364 [TBL] [Abstract][Full Text] [Related]
28. Co-occurrence of Fatigue and Depression in People With Multiple Sclerosis: A Mini-Review. Tarasiuk J; Kapica-Topczewska K; Czarnowska A; Chorąży M; Kochanowicz J; Kułakowska A Front Neurol; 2021; 12():817256. PubMed ID: 35242093 [TBL] [Abstract][Full Text] [Related]
29. Exploring Multiple Sclerosis (MS) and Amyotrophic Lateral Scler osis (ALS) as Neurodegenerative Diseases and their Treatments: A Review Study. Deeb O; Nabulsi M Curr Top Med Chem; 2020; 20(26):2391-2403. PubMed ID: 32972341 [TBL] [Abstract][Full Text] [Related]
30. Heart rate variability and fatigue in MS: two parallel pathways representing disseminated inflammatory processes? Garis G; Haupts M; Duning T; Hildebrandt H Neurol Sci; 2023 Jan; 44(1):83-98. PubMed ID: 36125573 [TBL] [Abstract][Full Text] [Related]
31. Incorporating patients' preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review. Ngorsuraches S; Poudel N Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):183-195. PubMed ID: 33472451 [No Abstract] [Full Text] [Related]
32. Disease modifying therapy management of multiple sclerosis after stem cell therapies: A retrospective case series. Manzano GS; Holroyd KB; Kaplan T; Bhattacharyya S; Chitnis T; Hotan G; Zurawski J; Galetta KM; Mateen FJ Mult Scler Relat Disord; 2022 Jul; 63():103861. PubMed ID: 35576727 [TBL] [Abstract][Full Text] [Related]